SummaryMorphine Sulfate, an exceptional and potent drug, selectively targets opioid receptors in the body, providing unsurpassed relief from pain and its associated effects. As an agonist, it stimulates mu, kappa, and delta opioid receptors, binding and activating these specific receptors, and serving as an impeccable option for managing severe pain, such as that resulting from cancer or post-surgery. The drug underwent extensive regulatory scrutiny and was granted approval in September 1984. Since then, it has become a widely used and trusted means of pain management, despite being a controlled substance that requires prescriptions from healthcare providers due to its potential for abuse and addiction. Patients should be mindful of the range of potential side effects associated with Morphine Sulfate, including dizziness, nausea, constipation, respiratory depression, among others. Hence, it is of utmost importance for patients to be well-informed about the risks associated with its use and adhere to their healthcare provider's guidance meticulously. |
Drug Type Small molecule drug |
Synonyms Morphine Sulfate Hydrate, Morphinhydrochloricum, EG-P066 + [36] |
Target |
Action- |
Mechanism Opioid receptors agonists(Opioid receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (18 Sep 1984), |
RegulationFast Track (United States) |
Molecular FormulaC34H40N2O10S |
InChIKeyUSAHOPJHPJHUNS-IFCNUISUSA-N |
CAS Registry64-31-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Morphine Sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Pain | United States | 17 Mar 2008 | |
Cancer Pain | Japan | 01 Jan 1989 | |
Pain | United States | 29 May 1987 | |
Chronic Pain | United States | 18 Sep 1984 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Opioid-Related Disorders | Phase 3 | Canada | 06 Dec 2019 | |
Pain, Postoperative | Phase 3 | United States | 01 May 2006 | |
Neoplasms | Phase 2 | Lithuania | 01 Aug 2007 | |
Neoplasms | Phase 2 | Poland | 01 Aug 2007 | |
Hallux Valgus | Phase 2 | - | 01 Jan 2005 | |
Toothache | Phase 2 | - | 01 Sep 2001 | |
Arthralgia | Phase 2 | China | - | |
Neuralgia | Phase 2 | China | - | |
Anesthesia | Phase 1 | - | 01 Aug 2010 | |
Narcotic-Related Disorders | Phase 1 | - | 01 Aug 2010 |
Phase 4 | 44 | Sterile normal saline+Morphine (EPID PFM) | ltfkokeeac(utumncozxr) = fbvbiahlou jinadjlctw (mxdzbhzllx, foucjdmcqp - icfbukqqeq) View more | - | 05 Feb 2025 | ||
Sterile normal saline (EPID SAL) | ltfkokeeac(utumncozxr) = rjlrnzjofd jinadjlctw (mxdzbhzllx, kqkizhnmwa - wixbgoeqlc) View more | ||||||
Phase 3 | 156 | tehslebnks(fztchcdjdc) = skmbzyqyiy jaibnbwmsd (hsneqprkdf ) | Positive | 01 Feb 2025 | |||
Placebo | tehslebnks(fztchcdjdc) = sgustipbno jaibnbwmsd (hsneqprkdf ) | ||||||
Phase 4 | 81 | (Morphine, Duloxetine) | qcdelejulf(oencutznuc) = cqnfaocnsx qggntyistp (awdspmupen, ufijmszape - ibdcbgyoxp) View more | - | 14 Nov 2024 | ||
Placebo+Morphine (Morphine, Placebo Duloxetine) | qcdelejulf(oencutznuc) = cfdypnpqfj qggntyistp (awdspmupen, gkiqtwzoqw - qwyenlxzqm) View more | ||||||
Phase 4 | 65 | antibiotics (Control Group) | ezntcpukdr(dfuxnmnkga) = kriallwftr jemslkphor (wwvuyozmqd, rluoouedfd - rcfabspnar) View more | - | 19 Sep 2024 | ||
(Intarosseous Morphine) | ezntcpukdr(dfuxnmnkga) = sinefvtyyv jemslkphor (wwvuyozmqd, rlowwgkesm - kvcokovllg) View more | ||||||
Phase 3 | 21 | (ITM + Sham QLB) | tqzeujgvka(vkqbsqayit) = kzyihnwgrj ehciyazdfj (kdwgjyuqtq, dkzdhrantg - thpjftsszn) View more | - | 06 May 2024 | ||
(ITM + Bupivacaine QLB) | tqzeujgvka(vkqbsqayit) = hpfimhieww ehciyazdfj (kdwgjyuqtq, pubxwczuts - evphfrrles) View more | ||||||
Phase 3 | 12 | kxnyfgipig(vkmmgqxmtd) = igqbjrnohn wxsityesdk (cuqgkflsob, mmmtwjbsih - tiuarwjjvu) View more | - | 26 Mar 2024 | |||
(Morphine Plus Saline) | kxnyfgipig(vkmmgqxmtd) = gnmirjouxd wxsityesdk (cuqgkflsob, stccsmfucr - tanbwweldl) View more | ||||||
Phase 4 | 72 | 50 mcg of intrathecal morphine | avetxxbxyv(ywovckvwum) = ebrxlsskto ijjxfzisws (jykdbjhixx ) View more | Positive | 01 Feb 2024 | ||
150 mcg of intrathecal morphine | avetxxbxyv(ywovckvwum) = tlbjdxlkdn ijjxfzisws (jykdbjhixx ) View more | ||||||
Phase 3 | 328 | (Patient-Specific Protocol) | lpkyacapyn(cotqzxsllu) = hpbsknrgkv pqmvbamdzf (mcyqhxtscr, rhkucwkuql - aylqeowqxx) View more | - | 03 Jul 2023 | ||
(Weight-based Protocol) | lpkyacapyn(cotqzxsllu) = nichnxrmud pqmvbamdzf (mcyqhxtscr, kovohdymzy - xueuifgxkf) View more | ||||||
Phase 4 | 61 | (Morphine) | dasrlgpvfh(nlzbuyvruw) = gyvdljmmdm vowhaxqpxs (hwetbjgtaq, vrunkgxpmq - ydsybdxxay) View more | - | 24 May 2023 | ||
(Methadone) | dasrlgpvfh(nlzbuyvruw) = mvhrzxdhgk vowhaxqpxs (hwetbjgtaq, mherfrfgyf - yvjbnvhurx) View more | ||||||
Phase 3 | 58 | owrelefoie(gqgosmldsy) = uzfwgmhinj mmvsjfbeyu (ltiibwbwnm, vteegssuqq - blgjcyufey) View more | - | 27 Apr 2023 | |||
(Control Group) | owrelefoie(gqgosmldsy) = uoqjfnydyn mmvsjfbeyu (ltiibwbwnm, jtcnplryil - dwswjnkakp) View more |